Next Article in Journal
Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease
Previous Article in Journal
Cutaneous Manifestations of Rheumatoid Arthritis: Diagnosis and Treatment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 13
Issue 10
10.3390/jpm13101480
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Relationship of Medication Intake and Systemic Conditions with Periodontitis: A Retrospective Study

by
Georgios S. Chatzopoulos
1,2,*,
Ziou Jiang
3,
Nicholas Marka
3 and
Larry F. Wolff
1
1
Division of Periodontology, Department of Developmental and Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA
2
Department of Preventive Dentistry, Periodontology and Implant Biology, Faculty of Dentistry, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3
Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN 55414, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2023, 13(10), 1480; https://doi.org/10.3390/jpm13101480
Submission received: 18 September 2023 / Revised: 4 October 2023 / Accepted: 7 October 2023 / Published: 10 October 2023
Versions Notes

Abstract

:
Objectives: To examine the potential relationship of medication intake and systemic conditions with periodontitis. Methods and Materials: A total of 1985 patient records with a diagnosis of periodontal health and stage III and IV periodontitis were included in the analysis. Demographic characteristics, the number of missing teeth, patient-reported medical conditions and medication intake as well as smoking habits were recorded. Regression models were performed to explore the outcomes. Results: Older individuals, Hispanic ethnic groups, Black and Hispanic or Latino racial groups and non-White individuals in general were significantly more frequently diagnosed with periodontitis than health. Hypertension, glaucoma, anxiety and depression were significantly associated with periodontitis, while cancer, alcohol use, kidney problems, asthma, sleep apnea and gastrointestinal disorders were associated with periodontal health. Patients who reported taking anticoagulants, statins and ACE inhibitors demonstrated 3.546 (95% CI: 1.982, 6.343), 2.771 (95% CI: 1.877, 4.09) and 4.847 (95% CI: 2.785, 8.434) times higher odds of having periodontitis, respectively. Conclusion: Within the limitations of this retrospective study that utilized the BigMouth dental data repository, there is a possible relationship between systemic medications including anticoagulants, ACE inhibitors and statins as well as systemic medical conditions including hypertension, glaucoma, anxiety and depression with periodontitis.

1. Introduction

Periodontal diseases are inflammatory diseases that exhibit multifactorial etiology and are initiated by microbial pathogens leading to tooth-supporting tissue destruction [1]. The development and progression of periodontal disease are a result of the interaction between pathogenic microorganisms as well as other parameters including genetics, environmental and lifestyle factors and the host-immune response [2,3]. Imbalances in the microbiota–immunity interactions which lead to the disruption of homeostasis and therefore disease onset may be affected by the systemic health condition of an individual [4].
Periodontitis development and progression may ultimately lead to tooth loss and edentulism, which may further cause masticatory dysfunction, poor nutrition, compromised speech and reduced quality of life [5]. This poses a significant socio-economic impact as well as increased healthcare costs [5]. Periodontal disease has a high prevalence globally and it is considered the sixth-most prevalent health condition, while its severe form of disease was estimated to affect 10.8% of the global population [6]. From 1990 to 2019, the global incidence of periodontitis increased by 83.4% revealing that current measures for periodontitis prevention are inadequate in controlling the disease worldwide [7]. In addition, the costs posed by periodontal disease in the United States and in 32 European countries in 2018 was estimated to be USD 154.06 billion and EUR 158.64 billion that year, respectively [8].
Over the years, a number of systemic conditions have been associated with periodontal disease. This has led to the development of a new term, “periodontal medicine”, to describe the relationship between systemic health and periodontal disease [9]. Periodontal disease has been linked to 57 systemic conditions, with the most common being diabetes, cardiovascular disease, obesity and preterm birth [10]. In addition, cancer, osteoporosis, thyroid disorders, depression, COPD, HIV, obstructive sleep apnea, pemphigus/pemphigoid and Down syndrome have been examined for their potential association with periodontal disease [11]. It is worth noting that periodontitis has been independently associated with the vast majority of chronic noncommunicable diseases of aging and premature mortality [12]. Tobacco, alcohol, medications, uncontrolled diabetes and obesity have been suggested as factors that should be taken into consideration for a personalized care model for the management of periodontal diseases [13]. In a cross-sectional pilot study from the Netherlands, periodontal disease was highly prevalent in multimorbidity patients, and significant associations were found in patients with cardiovascular diseases [14]. Systemic inflammatory conditions including hypertension, arthritis, asthma, diabetes and HIV were also found to be significantly associated with the severity of bone loss as well as diabetes, lupus and the extent of missing teeth in a retrospective study that included 4890 randomly selected patients [15]. Tobacco use has been recognized as a significant factor affecting periodontal disease onset, progression and treatment outcomes for several years [16,17]. Chronic inflammatory diseases share common causal factors including genetics and immune factors, which may explain their relationship [18]. Differences in the reported findings regarding the periodontal–systemic associations may be attributed to the inclusion of patients with a different severity and degree of systemic disease-control. Medication intake may reflect systemic disease severity and may explain their association with periodontitis.
A number of effects on periodontal tissues have been reported in the literature as a result of medication intake. Gingival enlargement, inflammation, pigmentations, gingival bleeding and osteonecrosis have been recorded. Drug-induced gingival overgrowth or enlargement is highly prevalent in patients taking phenytoin (anticonvulsant), cyclosporine (immunosuppressant), nifedipine and amlodipine (calcium channel blockers) [19]. Minocycline has been associated with pigmentations of the oral mucosa including buccal mucosa, gingiva, palates, lips and tongues [20]. Anti-platelets including aspirin and clopidogrel may increase gingival bleeding, especially following surgical treatment [21]. Bisphosphonates may also increase the risk of osteonecrosis following invasive dental treatment, while they may also be used locally as an adjunct treatment for scaling and root planing due to their antiresorptive properties [22,23]. A retrospective case-control study was aimed at investigating the potential association between medication consumption and the severity of periodontitis. Hypoglycemic agents, calcium channel blockers, insulin and diuretics were significantly higher in the periodontitis patients, while a higher intake frequency of angiotensin-converting enzyme (ACE) inhibitors and antidepressants was also found in the periodontitis group [24].
Early diagnosis has the potential to improve quality of life, preserve the natural dentition, maintain masticatory function and ultimately reduce the social and financial burden associated with periodontitis [5]. It is critically important to recognize systemic factors of an individual such as medications and inform the dental and medical community for potential associations with oral conditions such as periodontitis. Limited information is currently available in the literature surrounding the potential differences in regard to the medication intake between periodontitis and periodontally healthy individuals. Therefore, the aim of the present investigation was to examine the potential relationship of medication intake and systemic conditions with periodontitis.

2. Materials and Methods

This retrospective study was reviewed by the Institutional Review Board of the University of Minnesota, and it was determined that it is not research involving human subjects, as defined by the Department of Health and Human Services as well as the United States Food and Drug Administration (STUDY00016576). It was further reviewed and approved by the BigMouth Consortium for Oral Health Research and Informatics clinical review committee. This study was conducted in agreement with the Helsinki Declaration of 1975, as most recently revised in 2013. Data from the BigMouth Dental Data Repository used for this study were deidentified, and no extraction of personally identifiable information occurred. No recruitment of any patients and no access to patient identifiers were performed. The need for consent was thus waived.
The BigMouth Dental Data Repository was used to extract electronic health records from 2011 to 2021. Dental charts of adult patients who, seeking dental therapy, had attended the dental clinics of the universities contributing data to the BigMouth network and who accepted the protocol of the study were evaluated: Harvard University; University of Texas Health; The University of California, San Francisco; University of Colorado; Loma Linda University; University of Buffalo; The University of Iowa and The University of Minnesota. Electronic health records were entered during the patients’ visits by both dental students, residents and faculty oral healthcare providers. BigMouth is a centralized data repository that includes deidentified clinical data extracted from electronic health records at multiple institutions. Each participating institution controls the data it contributes and provides a “limited dataset” with deidentified data only. The technical team of BigMouth assesses the data quality when extracted from the participating institutions and after the load process through an automated script which compares the data received from all institutions with the previous extracts from the same institution. A system sanity checklist is also used to assess both the data quality and functionality of the BigMouth interface.
Dental Procedure Codes and Current Procedural Terminology procedures were utilized. Patients with at least one completed treatment code D0150 (comprehensive oral evaluation), D0120 (periodic oral evaluation provided to an established patient) or D0180 (comprehensive restorative and periodontal exam) were included. Only patients who completed any of the D0150, D0120 and D0180 treatment codes were included to ensure that included patients had comprehensive examination at any of the participating sites. Thus, patients who only had urgent treatment or limited oral examination were not included in the records. Patients’ records identified in the BigMouth Dental Data Repository with a periodontal diagnosis based on the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions were evaluated [25,26]. Initially, periodontitis patients were identified based on the following procedure codes: “D4210” or “D4211” or D4240” or “D4241” or “D4245” or “D4260” or “D4261” or “D4263” or “D4266” or “D4274” or “D4341” or “D4342” or “D4910”, which are used for the non-surgical and surgical treatment of periodontal disease. From the total population who had any of the above-mentioned treatment codes, individuals with stage III and stage IV periodontitis were identified by the use of the Dental Diagnostic System (DDS) (formerly known as EZCodes, which contains dental diagnostic terms), and they were solely included in the periodontitis group.
Individuals were categorized into periodontal health and periodontitis based on the periodontal diagnosis included in the electronic health records of the eligible dental records as follows:
-
Periodontal health: Gingival health is defined as <10% bleeding sites with probing depths ≤ 3 mm and no radiographic evidence of bone loss [25].
-
Periodontitis: Individuals with stage III and IV were included, who exhibit interdental clinical attachment loss of ≥5 mm and radiographic bone loss extending to the middle third of the root and beyond.
Data were extracted and validated from the electronic health records by independent data analysts at The University of Texas Health Science Center at Houston. Extracted data included:
-
Demographic characteristics: age (at baseline); ethnicity (Hispanic, non-Hispanic, other); race (Asian, African American, Pacific islander, American/Indian/Alaskan native, White, Hispanic or Latino, other); sex (male, female).
-
Number of missing teeth (at baseline).
-
Patient-reported medical conditions included the following: alcohol consumption, blood and hematological disorders, cancer, angina, congenital heart disease, coronary heart disease, history of endocarditis, heart attack, high blood pressure, implant defibrillator, rheumatic fever, smoking, cocaine use, marijuana use, adrenal gland disorder, diabetes, thyroid disorders, glaucoma, HIV, sexually transmitted disease, dialysis, kidney disease, renal failure or insufficiency, arthritis, lupus, osteoporosis, dementia, anxiety, depression, Parkinson disease, multiple sclerosis, seizure or epilepsy, stroke, organ transplantation, asthma, chronic bronchitis or emphysema, sleep apnea, Crohn’s disease, gastrointestinal disorder and hepatitis. Self-reported systemic diseases are based on a patient questionnaire that is completed at the initial visit and updated every 6–12 months.
-
Self-reported smoking habits (yes/no), as reported in the medical history form.
-
Patient-reported medication intake including: ACE inhibitors (Benazepril, Enalapril, Lisinopril, Quinapril, Ramipril); Antidepressants (fluoxetine, paroxetine, sertraline, citalopram, duloxetine, venlafaxine, desvenlafaxine, trazodone, mirtazapine, bupropion, nortriptyline, doxepin, quetiapine, aripiprazole, lithium, Amitryptiline); Anti-coagulants (Apixaban, Plavix, Xarelto, Brilinta, Cilostazol, Aspirin, Clopidogrel, Warfarin); Statins (Atorvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin); Biphosphonates (Zoledronic acid, ibandronate, alendronate, risedronate) and Proton Pump Inhibitors (Omeprazole, Lansoprazole, Dexilant, Esomeprazole, Pantoprazole).

Statistical Analysis

Patients’ demographic and clinical characteristics were summarized as means and standard deviations for continuous variables and as frequencies and percentages for categorical variables. Normality was assessed using density plots. Between healthy and periodontal disease patients, two sample t-tests and Chi-square tests were used for the comparison of continuous and categorical characteristics, respectively. Univariate associations between systemic medical conditions, medication intake and periodontal disease status were assessed using a logistic regression model, with the results presented as Odds Ratios (OR) and their corresponding 95% confidence intervals (CI). Multivariable regression models were explored for the above outcomes, adjusting for the effects of age, sex and missing teeth at baseline. For all multivariable regression models, p-values were corrected for multiple comparisons using the Hochberg method. All analyses were based on complete cases and were conducted at the 0.05 significance level using the R environment (R Foundation for Statistical Computing, Vienna, Austria (Version 4.2.1).

3. Results

The demographic characteristics of the included population are shown in Table 1. A total of 1985 patient records with a diagnosis of periodontal health and stage III and IV periodontitis according to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions were included in the analysis. Out of these records, 1099 patients were diagnosed with periodontitis (stage III and IV) and 886 with periodontal health. Significant differences were identified between the two groups with respect to age (p < 0.001), ethnicity (p < 0.001), race (p < 0.001) as well as the number of missing teeth (p < 0.001). Older individuals, Hispanic ethnic groups, Black and Hispanic or Latino racial groups and non-White individuals in general were significantly more frequently diagnosed with periodontitis than health. Periodontitis patients showed a significantly higher number of missing teeth than periodontally healthy individuals (p < 0.001).
The examined self-reported systemic medical conditions as well as alcohol use and smoking habits compared between periodontal health and periodontitis individuals are presented in Table 2. Forty-seven medical conditions as well as alcohol use, smoking habits including cigarettes, marijuana use, methamphetamine use and cocaine use were included in the analysis. Coronary heart disease, hypertension, implant defibrillator, marijuana use, diabetes, glaucoma, sexually transmitted diseases, arthritis, osteoporosis, depression, hepatitis and rheumatic fever were significantly (p < 0.005) more frequently reported by periodontitis patients. Cancer, alcohol use, asthma, sleep apnea, gastrointestinal disorders, anemia, bleeding disorders, cardiovascular diseases, anorexia, bulimia, bronchitis, respiratory or lung problems, sinusitis, tuberculosis and cirrhosis or chronic hepatitis were significantly (p < 0.005) more prevalent in the periodontally healthy patient group.
The multivariable regression analysis for the association between systemic medical conditions, alcohol use and smoking habits and periodontal status adjusted for age and sex is shown in Table 3. Individuals who reported hypertension, glaucoma, anxiety and depression exhibited significantly higher odds of having periodontitis (p < 0.05). In contrast, patients who reported cancer, alcohol use, kidney problems, asthma, sleep apnea and gastrointestinal disorders were significantly more likely to be associated with periodontal health (p < 0.05).
The medication types and the prevalence of consumption in the periodontitis and periodontal health groups are shown in Table 4. Six medication types/groups and forty-five medications were included in the analysis. All six medication types including bisphosphonates, proton pump inhibitors, antidepressants, anticoagulants, statins and ACE inhibitors were significantly associated with periodontitis. When specific medications were analyzed, esomeprazole, omeprazole, apixaban, xarelto, aspirin, clopidogrel, rosuvastatin, pravastatin, atorvastatin, simvastatin, ramipril, enalapril, lisinopril, sertraline and alendronate showed a statistically significantly higher (p < 0.05) intake frequency in the periodontitis group relative to the healthy group.
The multivariable regression analysis for the association between medication intake and periodontal status, adjusted for age and sex, is shown in Table 5. The adjusted odds ratios for the effects of medications between the periodontitis and healthy groups revealed that anticoagulants, statins and ACE inhibitors are significantly (p < 0.05) associated with periodontitis. Patients who reported taking anticoagulants, statins and ACE inhibitors demonstrated 3.546 (95% CI: 1.982, 6.343), 2.771 (95% CI: 1.877, 4.090) and 4.847 (95% CI: 2.785, 8.434) times higher odds of having periodontitis, respectively (p < 0.001).

4. Discussion

Limited information is available regarding the potential association between systemic medication intake and periodontal disease. The present study aimed at evaluating the relationship of medication intake and systemic conditions with periodontitis. Multivariable regression models were performed to explore these possible associations. Based on the data exported from dental charts of adult patients who, seeking dental therapy, had attended the dental clinics of the universities contributing data to the BigMouth network and had a diagnosis of periodontal health or stage III and IV periodontitis, the following findings are reported:
  • Older individuals, Hispanic ethnic groups, Black and Hispanic or Latino racial groups and non-White individuals in general were significantly more frequently diagnosed with periodontitis than health.
  • After adjusting for the effects of age, sex and missing teeth at baseline, patients with hypertension, glaucoma, anxiety and depression exhibited significantly higher odds of having periodontitis (p < 0.05), while patients with cancer, alcohol use, kidney problems, asthma, sleep apnea and gastrointestinal disorders were significantly associated with periodontal health (p < 0.005).
  • Following the adjustment for age, sex and the number of missing teeth at baseline, anticoagulants, statins and ACE inhibitors were significantly associated with periodontitis.
Diagnoses of moderate-severe and severe periodontitis have been associated with hypertension, while periodontal treatment leads to an improvement in hypertensive and prehypertensive individuals [27,28]. In addition, a systematic review of the literature showed that individuals with tooth loss exhibited a higher risk for hypertension, and hypertensive individuals have a higher risk of tooth loss [29]. Thus, this suggests a bidirectional association between tooth loss and hypertension [30]. In the present investigation, hypertensive patients were more likely associated with periodontitis, which is in agreement with the literature. In addition, glaucoma is a neurodegenerative disease that can be exacerbated by chronic systemic inflammation, which is a characteristic of periodontal disease [31]. It has also been reported that patients with glaucoma exhibit fewer natural teeth and a higher number of oral bacteria [32]. In a large retrospective population-based cohort study (n = 194,090) that utilized data from Taiwan’s National Health Insurance Research Database, glaucoma was highly prevalent among periodontitis patients when compared to periodontally healthy individuals, and the authors concluded that patients with periodontitis may increase the risk of glaucoma development compared with individuals without periodontitis [33]. These findings are consistent with the results of the present study.
In the present investigation, both depression and anxiety were highly associated with periodontitis. This is in agreement with findings reported in the literature. In a multicenter cross-sectional study, both anxiety and depression were highly prevalent among individuals with dental diseases, and a diagnosis of periodontitis was significantly associated with depression [34]. A systematic review of the literature demonstrated that psychological disorders including anxiety and depression were associated with greater tooth loss, while no association was found between psychological conditions and periodontal disease, except for panic disorder [35]. A more recent systematic review and meta-analysis that included 40 studies and evaluated the relationship of periodontal disease with depression and anxiety revealed that both psychological conditions were positively associated with periodontitis [36]. However, the researchers highlighted the high degree of heterogeneity among the publications [36]. Poorer oral hygiene practices, increased tobacco use as well as alcohol consumption, which are characteristics of individuals with mental health disorders, may be significant contributing factors [37]. Also, these associations may be explained by the immunomodulatory effects as well as the increased production of proinflammatory cytokines in individuals with such disorders [37]. Even the interaction of the gut microbiome with the central nervous system and, additionally, the role of the gut microbiome in the oral microbiome may be involved [37].
Periodontitis has been associated with a number of systemic conditions. However, the biological connections are still not clearly understood. Several theories have been proposed, including bacteremia, low-grade inflammation and increased myelopoietic activity. Bacteria or activated lymphocytes may disseminate from the oral cavity to distant tissues, leading to inflammatory and functional complications, which may therefore initiate comorbidities [38]. Inflammation in the oral cavity may induce an acute response and metabolic/inflammatory alterations in the liver and bone marrow, which can result in different systemic chronic inflammatory diseases [38]. In addition, patients with severe periodontitis exhibit elevated levels of pro-inflammatory mediators and increased neutrophil counts in the blood, which may explain the periodontal-systemic connection [38].
Anti-coagulants and antiplatelet medications including apixaban, plavix, xarelto, brilinta, cilostazol, aspirin, clopidogrel and warfarin were analyzed in the present study. Aspirin was the most frequently used anticoagulant in the study. Individuals who reported taking anticoagulants demonstrated 3.546 (95% CI: 1.982, 6.343) times higher odds of having periodontitis (p < 0.001). This may be attributed to the underlying cardiovascular diseases that are associated with chronic inflammation. Limited information is available regarding these medications. Low-dose aspirin has been investigated for its potential anti-inflammatory properties [39]. Low-dose aspirin has shown no association with periodontal status in a nationally representative sample of US adults, while another study demonstrated promising results as a host modulatory treatment when used as an adjunct to periodontal treatment [40,41]. A case-control study that included patients with generalized moderate to severe periodontitis and healthy individuals did not detect any significant associations between periodontal status and anticoagulant treatment [24]. Oral anticoagulants have been associated with an increased risk of osteoporosis due to their effect on bone metabolism and bone mineral density, primarily due to their impact on osteocalcin [42]. This may explain the increased risk of periodontitis in the present population.
In the examined group of statins, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were included. Individuals who reported statin intake showed 2.771 (95% CI: 1.877, 4.09) times higher odds of having periodontitis (p < 0.001). In a similar large longitudinal study that included 169,381 patients prescribed statins from the Korean National Health Insurance Service–Health Screening Cohort database between 2002 and 2015, the presence of chronic periodontitis was significantly more common in patients with long-term statin use (1–3 years, 3–5 years or >5 years) than in those with short-term use (≤1 year) [43]. It was also noted that, among long-term statin users, pre-existing periodontitis was uncommon, while newly occurring periodontitis was common, which reveals the effect of the medication on periodontal status [43]. In addition, the researchers reported a 1.32-fold higher rate of periodontitis occurrence in statin users [43]. It has also been reported in the literature that statin therapy is associated with a slightly increased risk of diabetes development, which may imply a possible dysregulation of the immune response of the host, which is crucial in periodontal stability [44]. Another interpretation is that, due to the anti-inflammatory effect of statins, the immune response may be dampened to protect against periodontal destruction [45]. This may ultimately lead to disruption of the immune homeostasis in periodontal tissues, leading to periodontal tissue breakdown [45]. Furthermore, elevated levels of serum lipids which are commonly found in patients with hypercholesterolemia are associated with periodontal infections [46]. In addition, a retrospective cohort study displayed a significant correlation between systemic statin use and peri-implant bone loss [47]. In contrast, other studies have found that statins may exhibit potential protective effects against tooth loss and may also lead to additional clinical benefits in conjunction with non-surgical periodontal therapy [48,49]. This potential effect has been attributed to their antimicrobial and antibiofilm activity as well as the stimulation of bone activity [50,51]. A dual effect of statins on the periodontium has been described, which is dependent on the inflammatory state of the periodontium [45].
ACE inhibitor use including benazepril, enalapril, lisinopril, quinapril and ramipril with respect to periodontal disease status was also analyzed in the present investigation. ACE inhibitors are commonly used for the treatment of hypertension. In this study, hypertension was found to be significantly associated with the presence of periodontitis, and moreover, the intake of ACE inhibitors was similarly associated with periodontal disease. In agreement with our finding, another study reported that individuals taking ACE inhibitors demonstrated a 3.2-fold higher risk of having sites with a pocket depth ≥ 5 mm and a 2.9-fold higher risk of having sites with clinical attachment loss ≥ 5 mm in comparison with those in the control group [52]. Patients undergoing antihypertensive therapy with ACE inhibitors may have an increased risk of periodontal disease onset as a result of the elevations in kinin activity due to the inactivation of ACE [53] ACE inhibitors may also trigger dendritic cells to produce IL-12 through the activation of B(2) bradykinin receptors, which has been associated with the pathogenesis of periodontal disease [54,55].
Periodontitis is a complex multifactorial chronic inflammatory disease which is a result of the interactions between genetics and environment [18]. In the present study, Hispanic ethnic groups, Black and Hispanic or Latino racial groups and non-White individuals in general were significantly more frequently diagnosed with periodontitis than health. Cultural and genetic factors may contribute to the observed variations in periodontal health among different ethnic and racial groups. In regard to genetics, population-specific risk gene variants have been identified in the literature [56,57]. In addition, periodontitis disparity amongst different racial/ethnic groups has been documented with African Americans and Hispanics demonstrating a higher incidence of periodontitis [58,59].
It is of paramount importance to consider the inherent limitations of this retrospective study. Although it is impossible to demonstrate causality between risk factors and periodontal disease, it may provide evidence for potential risk indicators that can lead to future studies. Future studies may also investigate the impact of socioeconomic factors on medication intake for individuals with periodontitis. The diagnosis of periodontal health and periodontitis was based on the periodontal diagnosis included in the electronic health records of the eligible dental records evaluated. No clinical examination or evaluation of clinical and radiographic data were performed for the purpose of this study. Possible additive, synergistic or antagonistic effects due to drug–drug interactions could not be examined in this investigation. Self-reported medical history and medication intake were utilized in the present investigation to determine their association with periodontal disease. The retrospective study design did not allow for serum collection, which could provide more insights regarding the patients’ medical status. The presence of confounding factors or other biases could not be examined to an extent. Moreover, no information regarding specific dosages or durations of medication intake was available for all of the included patients, and therefore, no statistical analysis was performed. Future studies should further explore the association between medication usage and periodontitis onset and progression. The potential dose- and duration-dependent effects should be examined in the future. Prospective or longitudinal investigations are also needed to include serum-based findings as well as rule out confounding factors.
A strength of this investigation was the use of data from a large record database (BigMouth) that has in-depth information on patients’ dental and medical histories, derived from a variety of institutions and providers. Pooling datasets from different sources provides greater insight into the types of patients taking specific medications and who may be at risk of periodontitis. In addition, in the published literature, limited data are currently available regarding the effect of systemic medications on periodontal status, and this investigation explores this potential association and provides evidence for possible relationships obtained from a large database of multiple dental schools. Oral health is considered part of general health, and based on the findings of the present investigation, systemic medical conditions and medication intake are associated with periodontal disease. Therefore, both dental clinicians and general practitioners should be aware of these findings to inform their patients about these relationships. The cooperation between medical and dental professionals is crucial.

5. Conclusions

Within the limitations of this retrospective study that utilized the BigMouth dental data repository, there is a possible relationship between systemic medications including anticoagulants, ACE inhibitors and statins as well as systemic medical conditions including hypertension, glaucoma, anxiety and depression and periodontitis. Future studies should further explore the association between medication usage and periodontitis onset and progression in prospective or longitudinal investigations taking into consideration potential confounding factors. The potential dose- and duration-dependent effects should be examined.

Author Contributions

G.S.C. contributed to the study conception, study design, data collection and draft of the manuscript; Z.J. and N.M. contributed to the study design and data collection; L.F.W. contributed to the study conception and critical review of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1-TR002494 and COHRI-BM-DR25. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was further supported by a University of Minnesota School of Dentistry, Division of Periodontology grant (L.F.W.).

Institutional Review Board Statement

The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations. The Institutional Review Board of the University of Minnesota determined that it is not research involving human subjects, as defined by the Department of Health and Human Services, as well as the United States Food and Drug Administration, and it was approved for data extraction and analysis (STUDY00016576, 13 July 2022). It was further reviewed and approved by the BigMouth Consortium for Oral Health Research and Informatics clinical review committee (COHRI-BM-DR25). This study was conducted in agreement with the Helsinki Declaration of 1975, as most recently revised in 2013.

Informed Consent Statement

Data from the BigMouth Dental Data Repository used for this study were deidentified, and no extraction of personally identifiable information occurred. No recruitment of any patients and no access to patient identifiers were performed. The need for consent was thus waived.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments

Data for this research were obtained from the BigMouth Dental Data Repository. The authors would like to thank the Consortium for Oral Health Research and Informatics clinical research committee.

Conflicts of Interest

The authors report no conflict of interest related to this study.

References

  1. Offenbacher, S. Periodontal diseases: Pathogenesis. Ann. Periodontol. 1996, 1, 821–878. [Google Scholar] [CrossRef] [PubMed]
  2. Genco, R.J.; Sanz, M. Clinical and public health implications of periodontal and systemic diseases: An overview. Periodontology 2000 2020, 83, 7–13. [Google Scholar] [CrossRef] [PubMed]
  3. Joseph, S.; Curtis, M.A. Microbial transitions from health to disease. Periodontology 2000 2021, 86, 201–209. [Google Scholar] [CrossRef] [PubMed]
  4. Zheng, D.; Liwinski, T.; Elinav, E. Interaction between microbiota and immunity in health and disease. Cell. Res. 2020, 30, 492–506. [Google Scholar] [CrossRef] [PubMed]
  5. Tonetti, M.S.; Jepsen, S.; Jin, L.; Otomo-Corgel, J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: A call for global action. J. Clin. Periodontol. 2017, 44, 456–462. [Google Scholar] [CrossRef] [PubMed]
  6. Kassebaum, N.J.; Bernabé, E.; Dahiya, M.; Bhandari, B.; Murray, C.J.L.; Marcenes, W. Global burden of severe periodontitis in 1990-2010: A systematic review and meta-regression. J. Dent. Res. 2014, 93, 1045–1053. [Google Scholar] [CrossRef] [PubMed]
  7. Wu, L.; Zhang, S.Q.; Zhao, L.; Ren, Z.H.; Hu, C.Y. Global, regional, and national burden of periodontitis from 1990 to 2019: Results from the Global Burden of Disease study 2019. J. Periodontol. 2022, 93, 1445–1454. [Google Scholar] [CrossRef]
  8. Botelho, J.; Machado, V.; Leira, Y.; Proença, L.; Chambrone, L.; Mendes, J.J. Economic burden of periodontitis in the United States and Europe: An updated estimation. J. Periodontol. 2022, 93, 373–379. [Google Scholar] [CrossRef]
  9. Williams, R.C.; Offenbacher, S. Periodontal medicine: The emergence of a new branch of periodontology. Periodontology 2000 2000, 23, 9–12. [Google Scholar] [CrossRef]
  10. Monsarrat, P.; Blaizot, A.; Kémoun, P.; Ravaud, P.; Nabet, C.; Sixou, M.; Vergnes, J.N. Clinical research activity in periodontal medicine: A systematic mapping of trial registers. J. Clin. Periodontol. 2016, 43, 390–400. [Google Scholar] [CrossRef]
  11. Natto, Z.S.; Hameedaldain, A. Methodological Quality Assessment of Meta-analyses and Systematic Reviews of the Relationship Between Periodontal and Systemic Diseases. J. Evid. Based Dent. Pract. 2019, 19, 131–139. [Google Scholar] [CrossRef]
  12. Söder, B.; Jin, L.J.; Klinge, B.; Söder, P.O. Periodontitis and premature death: A 16-year longitudinal study in a Swedish urban population. J. Periodontal Res. 2007, 42, 361–366. [Google Scholar] [CrossRef]
  13. Bartold, P.M. Lifestyle and periodontitis: The emergence of personalized periodontics. Periodontology 2000 2018, 78, 7–11. [Google Scholar] [CrossRef]
  14. Leung, T.J.T.; Nijland, N.; Gerdes, V.E.A.; Loos, B.G. Prevalence of Periodontal Disease among Patients at the Outpatient Clinic of Internal Medicine in an Academic Hospital in The Netherlands: A Cross-Sectional Pilot Study. J. Clin. Med. 2022, 11, 6018. [Google Scholar] [CrossRef]
  15. Chatzopoulos, G.S.; Cisneros, A.; Sanchez, M.; Wolff, L.F. Association between Periodontal Disease and Systemic Inflammatory Conditions Using Electronic Health Records: A Pilot Study. Antibiotics 2021, 10, 386. [Google Scholar] [CrossRef]
  16. Ismail, A.I.; Burt, B.A.; Eklund, S.A. Epidemiologic patterns of smoking and periodontal disease in the United States. J. Am. Dent. Assoc. 1983, 106, 617–621. [Google Scholar] [CrossRef]
  17. Chatzopoulos, G.S.; Jiang, Z.; Marka, N.; Wolff, L.F. Association between Periodontitis Extent, Severity, and Progression Rate with Systemic Diseases and Smoking: A Retrospective Study. J. Pers. Med. 2023, 13, 814. [Google Scholar] [CrossRef] [PubMed]
  18. Loos, B.G.; Van Dyke, T.E. The role of inflammation and genetics in periodontal disease. Periodontology 2000 2020, 83, 26–39. [Google Scholar] [CrossRef] [PubMed]
  19. Heasman, P.A.; Hughes, F.J. Drugs, medications and periodontal disease. Br. Dent. J. 2014, 217, 411–419. [Google Scholar] [CrossRef]
  20. LaPorta, V.N.; Nikitakis, N.G.; Sindler, A.J.; Reynolds, M.A. Minocycline-associated intra-oral soft-tissue pigmentation: Clinicopathologic correlations and review. J. Clin. Periodontol. 2005, 32, 119–122. [Google Scholar] [CrossRef] [PubMed]
  21. Elad, S.; Chackartchi, T.; Shapira, L.; Findler, M. A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet. J. Clin. Periodontol. 2008, 35, 342–345. [Google Scholar] [CrossRef] [PubMed]
  22. Anil, S.; Preethanath, R.S.; AlMoharib, H.S.; Kamath, K.P.; Anand, P.S. Impact of osteoporosis and its treatment on oral health. Am. J. Med. Sci. 2013, 346, 396–401. [Google Scholar] [CrossRef]
  23. Akram, Z.; Abduljabbar, T.; Kellesarian, S.V.; Abu Hassan, M.I.; Javed, F.; Vohra, F. Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of periodontal disease: A systematic review. Br. J. Clin. Pharmacol. 2017, 83, 444–454. [Google Scholar] [CrossRef]
  24. Wang, I.C.; Askar, H.; Ghassib, I.; Wang, C.W.; Wang, H.L. Association between periodontitis and systemic medication intake: A case-control study. J. Periodontol. 2020, 91, 1245–1255. [Google Scholar] [CrossRef] [PubMed]
  25. Chapple, I.L.; Mealey, B.L.; Van Dyke, T.E.; Bartold, P.M.; Dommisch, H.; Eickholz, P.; Geisinger, M.L.; Genco, R.J.; Glogauer, M.; Goldstein, M.; et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Periodontol. 2018, 89 (Suppl. S1), S74–S84. [Google Scholar] [CrossRef]
  26. Papapanou, P.N.; Sanz, M.; Buduneli, N.; Dietrich, T.; Feres, M.; Fine, D.H.; Flemmig, T.F.; Garcia, R.; Giannobile, W.V.; Graziani, F.; et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Periodontol. 2018, 89 (Suppl. S1), S173–S182. [Google Scholar] [CrossRef] [PubMed]
  27. Munoz Aguilera, E.; Suvan, J.; Buti, J.; Czesnikiewicz-Guzik, M.; Barbosa Ribeiro, A.; Orlandi, M.; Guzik, T.J.; Hingorani, A.D.; Nart, J.; D’Aiuto, F. Periodontitis is associated with hypertension: A systematic review and meta-analysis. Cardiovasc. Res. 2020, 116, 28–39. [Google Scholar] [CrossRef]
  28. Sharma, S.; Sridhar, S.; McIntosh, A.; Messow, C.M.; Aguilera, E.M.; Del Pinto, R.; Pietropaoli, D.; Gorska, R.; Siedlinski, M.; Maffia, P.; et al. Periodontal therapy and treatment of hypertension-alternative to the pharmacological approach. A systematic review and meta-analysis. Pharmacol. Res. 2021, 166, 105511. [Google Scholar] [CrossRef]
  29. Xu, K.; Yu, W.; Li, Y.; Li, Y.; Wan, Q.; Chen, L.; Dong, Y.; Tay, F.R.; Niu, L. Association between tooth loss and hypertension: A systematic review and meta-analysis. J. Dent. 2022, 123, 104178. [Google Scholar] [CrossRef]
  30. Cardoso, E.M.; Reis, C.; Manzanares-Céspedes, M.C. Chronic periodontitis, inflammatory cytokines, and interrelationship with other chronic diseases. Postgrad. Med. 2018, 130, 98–104. [Google Scholar] [CrossRef]
  31. Vohra, R.; Tsai, J.C.; Kolko, M. The role of inflammation in the pathogenesis of glaucoma. Surv. Ophthalmol. 2013, 58, 311–320. [Google Scholar] [CrossRef] [PubMed]
  32. Polla, D.; Astafurov, K.; Hawy, E.; Hyman, L.; Hou, W.; Danias, J. A Pilot Study to Evaluate the Oral Microbiome and Dental Health in Primary Open-Angle Glaucoma. J. Glaucoma. 2017, 26, 320–327. [Google Scholar] [CrossRef] [PubMed]
  33. Sun, K.T.; Shen, T.C.; Chen, S.C.; Chang, C.L.; Li, C.H.; Li, X.; Palanisamy, K.; Hsia, N.Y.; Chang, W.S.; Tsai, C.W.; et al. Periodontitis and the subsequent risk of glaucoma: Results from the real-world practice. Sci. Rep. 2020, 10, 17568. [Google Scholar] [CrossRef]
  34. Seifu, B.; Yigzaw, N.; Haile, K.; Reshid, Z.; Asfaw, H. Prevalence of depression, anxiety and associated factors among patients with dental disease attending outpatient department in Addis Ababa public hospitals, Addis Ababa, Ethiopia: A multicenter cross-sectional study. BMC Oral. Health 2021, 21, 635. [Google Scholar] [CrossRef]
  35. Kisely, S.; Sawyer, E.; Siskind, D.; Lalloo, R. The oral health of people with anxiety and depressive disorders—A systematic review and meta-analysis. J. Affect. Disord. 2016, 200, 119–132. [Google Scholar] [CrossRef]
  36. Zheng, D.X.; Kang, X.N.; Wang, Y.X.; Huang, Y.N.; Pang, C.F.; Chen, Y.X.; Kuang, Z.L.; Peng, Y. Periodontal disease and emotional disorders: A meta-analysis. J. Clin. Periodontol. 2021, 48, 180–204. [Google Scholar] [CrossRef]
  37. Ball, J.; Darby, I. Mental health and periodontal and peri-implant diseases. Periodontology 2000 2022, 90, 106–124. [Google Scholar] [CrossRef]
  38. Hajishengallis, G.; Chavakis, T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat. Rev. Immunol. 2021, 21, 426–440. [Google Scholar] [CrossRef] [PubMed]
  39. Drouganis, A.; Hirsch, R. Low-dose aspirin therapy and periodontal attachment loss in ex- and non-smokers. J. Clin. Periodontol. 2001, 28, 38–45. [Google Scholar] [CrossRef]
  40. Kotsakis, G.A.; Thai, A.; Ioannou, A.L.; Demmer, R.T.; Michalowicz, B.S. Association between low-dose aspirin and periodontal disease: Results from the continuous national health and nutrition examination survey (NHANES) 2011-2012. J. Clin. Periodontol. 2015, 42, 333–341. [Google Scholar] [CrossRef]
  41. El-Sharkawy, H.; Aboelsaad, N.; Eliwa, M.; Darweesh, M.; Alshahat, M.; Kantarci, A.; Hasturk, H.; Van Dyke, T.E. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin. J. Periodontol. 2010, 81, 1635–1643. [Google Scholar] [CrossRef]
  42. Signorelli, S.S.; Scuto, S.; Marino, E.; Giusti, M.; Xourafa, A.; Gaudio, A. Anticoagulants and Osteoporosis. Int. J. Mol. Sci. 2019, 20, 5275. [Google Scholar] [CrossRef]
  43. Kwon, M.J.; Byun, S.H.; Kim, J.H.; Kim, J.H.; Kim, S.H.; Kim, N.Y.; Park, H.R.; Choi, H.G. Longitudinal follow-up study of the association between statin use and chronic periodontitis using national health screening cohort of Korean population. Sci. Rep. 2022, 12, 5504. [Google Scholar] [CrossRef]
  44. Sattar, N.; Preiss, D.; Murray, H.M.; Welsh, P.; Buckley, B.M.; de Craen, A.J.; Seshasai, S.R.; McMurray, J.J.; Freeman, D.J.; Jukema, J.W.; et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010, 375, 735–742. [Google Scholar] [CrossRef] [PubMed]
  45. Saxlin, T.; Suominen-Taipale, L.; Knuuttila, M.; Alha, P.; Ylöstalo, P. Dual effect of statin medication on the periodontium. J. Clin. Periodontol. 2009, 36, 997–1003. [Google Scholar] [CrossRef]
  46. Nibali, L.; D’Aiuto, F.; Griffiths, G.; Patel, K.; Suvan, J.; Tonetti, M.S. Severe periodontitis is associated with systemic inflammation and a dysmetabolic status: A case-control study. J. Clin. Periodontol. 2007, 34, 931–937. [Google Scholar] [CrossRef] [PubMed]
  47. Bahrami-Hessari, B.; Jansson, L. Peri-implant marginal bone loss and systemic statin use: A retrospective cohort pilot study. Clin. Exp. Dent. Res. 2022, 8, 20–27. [Google Scholar] [CrossRef] [PubMed]
  48. Meisel, P.; Kroemer, H.K.; Nauck, M.; Holtfreter, B.; Kocher, T. Tooth loss, periodontitis, and statins in a population-based follow-up study. J. Periodontol. 2014, 85, e160–e168. [Google Scholar] [CrossRef] [PubMed]
  49. Donos, N.; Calciolari, E.; Brusselaers, N.; Goldoni, M.; Bostanci, N.; Belibasakis, G.N. The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies. J. Clin. Periodontol. 2020, 47 (Suppl. S22), 199–238. [Google Scholar] [CrossRef]
  50. De Carvalho, R.D.; de Andrade Moreno, J.; Roque, S.M.; Chan, D.C.; Torrez, W.B.; Stipp, R.N.; Bueno-Silva, B.; de Lima, P.O.; Cogo-Müller, K. Statins and oral biofilm: Simvastatin as a promising drug to control periodontal dysbiosis. Oral. Dis. 2022. [Google Scholar] [CrossRef]
  51. De Carvalho, R.D.P.; Casarin, R.C.V.; de Lima, P.O.; Cogo-Müller, K. Statins with potential to control periodontitis: From biological mechanisms to clinical studies. J. Oral. Biosci. 2021, 63, 232–244. [Google Scholar] [CrossRef]
  52. Rodrigues, M.; Barbirato, D.; Luiz, R.R.; Scharfstein, J.; Salles, G.F.; Feres-Filho, E.J. Effect of antihypertensive therapy with angiotensin-converting enzyme inhibitors on chronic periodontitis: A case-control study. Oral. Dis. 2016, 22, 791–796. [Google Scholar] [CrossRef] [PubMed]
  53. Dykewicz, M.S. Cough and angioedema from angiotensin-converting enzyme inhibitors: New insights into mechanisms and management. Curr. Opin. Allergy Clin. Immunol. 2004, 4, 267–270. [Google Scholar] [CrossRef] [PubMed]
  54. Aliberti, J.; Viola, J.P.; Vieira-de-Abreu, A.; Bozza, P.T.; Sher, A.; Scharfstein, J. Cutting edge: Bradykinin induces IL-12 production by dendritic cells: A danger signal that drives Th1 polarization. J. Immunol. 2003, 170, 5349–5353. [Google Scholar] [CrossRef]
  55. Tsai, I.S.; Tsai, C.C.; Ho, Y.P.; Ho, K.Y.; Wu, Y.M.; Hung, C.C. Interleukin-12 and interleukin-16 in periodontal disease. Cytokine 2005, 31, 34–40. [Google Scholar] [CrossRef] [PubMed]
  56. Schäfer, A.S.; Van der Velden, U.; Laine, M.L.; Loos, B.G. Genetic susceptibility to periodontal disease: New insights and challenges. In Clinical Periodontology and Implant Dentistry; Lindhe, J., Lang, N.P., Eds.; Wiley Blackwell: Chichester, UK, 2015; pp. 290–310. [Google Scholar]
  57. Gonçalves, P.F.; Harris, T.H.; Elmariah, T.; Aukhil, I.; Wallace, M.R.; Shaddox, L.M. Genetic polymorphisms and periodontal disease in populations of African descent: A review. J. Periodontal Res. 2018, 53, 164–173. [Google Scholar] [CrossRef]
  58. Borrell, L.N.; Burt, B.A.; Gillespie, B.W.; Lynch, J.; Neighbors, H. Periodontitis in the United States: Beyond black and white. J. Public. Health Dent. 2002, 62, 92–101. [Google Scholar] [CrossRef]
  59. Eke, P.I.; Dye, B.A.; Wei, L.; Slade, G.D.; Thornton-Evans, G.O.; Borgnakke, W.S.; Taylor, G.W.; Page, R.C.; Beck, J.D.; Genco, R.J. Update on Prevalence of Periodontitis in Adults in the United States: NHANES 2009 to 2012. J. Periodontol. 2015, 86, 611–622. [Google Scholar] [CrossRef]
Table 1. Demographic characteristics of the included population.
Table 1. Demographic characteristics of the included population.
CharacteristicsTotal Population
n = 1985		Periodontal Health
n = 886		Periodontitis
n = 1099		p-Value
AGE (mean (SD))48.34 (17.7)39.40 (18.3)55.55 (13.4)<0.001
SEX (%)FEMALE1043 (52.5)462 (52.1)581 (52.9)0.783
MALE942 (47.5)424 (47.9)518 (47.1)
ETHNICITY (%)NON-HISPANIC822 (58.8)663 (79.6)159 (28.1)<0.001
HISPANIC523 (37.4)128 (15.4)395 (69.8)
OTHERS54 (3.9)42 (5.0)12 (2.1)
RACE (%)WHITE830 (41.8)506 (57.1)324 (29.5)
AMERICAN INDIAN5 (0.3)2 (0.2)3 (0.3)0.353
ASIAN206 (10.4)92 (10.4)114 (10.4)<0.001
BLACK311 (15.7)95 (10.7)216 (19.7)<0.001
HISPANIC OR LATINO376 (18.9)2 (0.2)374 (34.0)<0.001
OTHERS154 (7.8)130 (14.7)24 (2.2)<0.001
PACIFIC ISLANDER2 (0.1)2 (0.2)0 (0.0)0.972
TWO OR MORE101 (5.1)57 (6.4)44 (4.0)0.380
RACE White (%)NON-WHITE1106 (55.7)354 (40.0)752 (68.4)<0.001
WHITE879 (44.3)532 (60.0)347 (31.6)
Missing teeth (mean (SD))1.54 (2.7)0.46 (1.2)2.41 (3.2)<0.001
Two sample t-tests and Chi-square tests were used for the comparison of continuous and categorical characteristics between healthy and periodontal disease patients. Bold denotes significance.
Table 2. Examined self-reported systemic medical conditions as well as alcohol use and smoking habits compared between periodontal health and periodontitis individuals.
Table 2. Examined self-reported systemic medical conditions as well as alcohol use and smoking habits compared between periodontal health and periodontitis individuals.
Self-Reported Medical Condition, Alcohol Use and SmokingPeriodontal Health
n = 886		Periodontitis n = 1099p-Value
BLOOD HEMOTOLOGICAL DISORDERS (%)16 (1.8)27 (2.5)0.355
CANCER (%)51 (5.8)38 (3.5)0.016
ANGINA (%)3 (0.3)8 (0.7)0.364
CONGENITAL HEART DISEASE (%)5 (0.6)8 (0.7)0.783
CORONARY HEART DISEASE (%)4 (0.5)25 (2.3)0.001
HEART ATTACK (%)7 (0.8)12 (1.1)0.644
HYPERTENSION (%)106 (12.0)447 (40.7)<0.001
IMPLANT DEFIBRILLATOR (%)6 (0.7)26 (2.4)0.003
CIGARETTES (%)59 (6.7)69 (6.3)0.783
ALCOHOL USE (%)454 (51.2)346 (31.5)<0.001
MARIJUANA USE (%)21 (2.4)45 (4.1)0.043
DIABETES (%)55 (6.2)127 (11.6)<0.001
THYROID PROBLEMS (%)52 (5.9)71 (6.5)0.640
GLAUCOMA (%)9 (1.0)167 (15.2)<0.001
HIV (%)1 (0.1)4 (0.4)0.389
SEXUALLY TRANSMITTED DISEASES (%)3 (0.3)14 (1.3)0.027
DIALYSIS (%)2 (0.2)5 (0.5)0.471
KIDNEY (%)46 (5.2)55 (5.0)0.918
RENAL FAILURE OR INSUFFICIENCY (%)8 (0.9)19 (1.7)0.123
ARTHRITIS (%)70 (7.9)203 (18.5)<0.001
OSTEOPOROSIS (%)10 (1.1)67 (6.1)<0.001
ANXIETY (%)20 (2.3)72 (6.6)<0.001
DEPRESSION (%)16 (1.8)80 (7.3)<0.001
PARKINSON’S DISEASE (%)1 (0.1)4 (0.4)0.389
MULTIPLE SCLEROSIS (%)2 (0.2)1 (0.1)0.589
SEIZURE OR EPILEPSY (%)9 (1.0)11 (1.0)>0.99
STROKE (%)4 (0.5)13 (1.2)0.090
ORGAN TRANSPLANT (%)5 (0.6)6 (0.5)>0.99
ASTHMA (%)54 (6.1)3 (0.3)<0.001
CHRONIC BRONCHITIS OR EMPHYSEMA (%)7 (0.8)9 ( 0.8)>0.99
SLEEP APNEA (%)20 (2.3)3 (0.3)<0.001
CROHN’S DISEASE (%)4 (0.5)7 (0.6)0.764
GASTROINTESTINAL DISORDERS (%)50 (5.6)5 (0.5)<0.001
HEPATITIS (%)16 (1.8)55 (5.0)<0.001
ANEMIA (%)16 (1.8)0 (0.0)<0.001
BLEEDING DISORDERS (%)4 (0.5)0 (0.0)0.040
LEUKEMIA (%)3 (0.3)0 (0.0)0.089
CARDIOVASCULAR DISEASES (%)170 (19.2)0 (0.0)<0.001
HISTORY OF ENDOCARDITIS (%)1 (0.1)0 (0.0)0.446
COCAINE USE (%)1 (0.1)0 (0.0)0.446
METHAMPHETAMINE USE (%)1 (0.1)0 (0.0)0.446
ANOREXIA (%)6 (0.7)0 (0.0)0.008
BULIMIA (%)5 (0.6)0 (0.0)0.018
BRONCHITIS (%)50 (5.6)0 (0.0)<0.001
RESPIRATORY OR LUNG PROBLEM (%)49 (5.5)0 (0.0)<0.001
SINUSITIS (%)83 (9.4)0 (0.0)<0.001
TUBERCULOSIS (%)25 (2.8)0 (0.0)<0.001
CIRRHOSIS OR CHRONIC HEPATITIS (%)18 (2.0)0 (0.0)<0.001
RHEUMATIC FEVER (%)0 (0.0)8 (0.7)0.010
ANDRENAL GLAND DISORDER (%)0 (0.0)2 (0.2)0.506
LUPUS (%)0 (0.0)2 (0.2)0.506
DEMENTIA (%)0 (0.0)4 (0.4)0.133
Bold denotes significance. Univariate associations between systemic medical conditions and periodontal disease status were assessed using a logistic regression model.
Table 3. Multivariable regression analysis for the association between systemic medical conditions, alcohol use, smoking habits and periodontal status adjusted for age and sex.
Table 3. Multivariable regression analysis for the association between systemic medical conditions, alcohol use, smoking habits and periodontal status adjusted for age and sex.
Self-Reported Medical Condition, Alcohol Use and SmokingAdjusted OR (95% CI)p-Value
BLOOD HEMOTOLOGICAL DISORDERS0.647 (0.307, 1.364)0.998
CANCER 0.161 (0.094, 0.271)<0.001
ANGINA 1.484 (0.343, 6.426)0.998
CONGENITAL HEART DISEASE 0.412 (0.106, 1.607)0.998
CORONARY HEART DISEASE 1.161 (0.376, 3.591)0.998
HEART ATTACK 0.385 (0.137, 1.082)0.998
HYPERTENSION 2.035 (1.536, 2.682)<0.001
IMPLANT DEFIBRILLATOR 1.181 (0.421, 3.317)0.998
CIGARETTES 0.537 (0.351, 0.822)0.097
ALCOHOL USE 0.459 (0.367, 0.574)<0.001
MARIJUANA USE 2.251 (1.201, 4.221)0.262
DIABETES 0.786 (0.535, 1.155)0.998
THYROID PROBLEMS 0.639 (0.412, 0.997)0.998
GLAUCOMA 8.368 (4.102, 17.069)<0.001
HIV 2.388 (0.241, 23.700)0.998
SEXUALLY TRANSMITTED DISEASES 2.498 (0.606, 10.296)0.998
DIALYSIS 0.840 (0.124, 5.686)0.998
KIDNEY 0.401 (0.249, 0.646)0.004
RENAL FAILURE OR INSUFFICIENCY 0.863 (0.337, 2.215)0.998
ARTHRITIS 1.088 (0.774, 1.529)0.998
OSTEOPOROSIS 2.327 (1.139, 4.755)0.452
ANXIETY 2.651 (1.499, 4.688)0.020
DEPRESSION 3.864 (2.102, 7.103)<0.001
PARKINSON’S DISEASE 0.997 (0.101, 9.977)0.998
MULTIPLE SCLEROSIS 0.402 (0.030, 5.332)0.998
SEIZURE OR EPILEPSY 0.803 (0.271, 2.393)0.998
STROKE 1.011 (0.301, 3.396)0.998
ORGAN TRANSPLANT 0.372 (0.104, 1.332)0.998
ASTHMA 0.019 (0.005, 0.081)<0.001
CHRONIC BRONCHITIS OR EMPHYSEMA 0.589 (0.185, 1.875)0.998
SLEEP APNEA 0.034 (0.008, 0.138)<0.001
CROHN’S DISEASE 1.841 (0.432, 7.856)0.998
GASTROINTESTINAL DISORDERS 0.062 (0.022, 0.175)<0.001
HEPATITIS 1.389 (0.743, 2.612)0.998
Bold denotes significance. Multivariable regression models were explored, adjusting for the effects of age, sex and missing teeth at baseline. p-values were corrected for multiple comparisons using the Hochberg method.
Table 4. Medication types and prevalence of consumption in the periodontitis and periodontal health groups.
Table 4. Medication types and prevalence of consumption in the periodontitis and periodontal health groups.
MedicationsPeriodontal Health
n = 886		Periodontitis
n = 1099		p-Value
BIPHOSPHONATES (%)6 (0.7)22 (2.0)0.022
PROTON PUMP INHIBITORS (%)20 (2.3)83 (7.6)<0.001
ANTIDEPRESSANTS (%)56 (6.3)105 (9.6)0.011
ANTICOAGULANTS (%)15 (1.7)140 (12.7)<0.001
STATINS (%)38 (4.3)239 (21.7)<0.001
ACE INHIBITORS (%)16 (1.8)154 (14.0)<0.001
PANTOPRAZOLE (%)1 (0.1)25 (2.3)<0.001
LANSOPRAZOLE (%)3 (0.3)1 (0.1)0.330
ESOMEPRAZOLE (%)3 (0.3)14 (1.3)0.027
DEXILANT (%)1 (0.1)1 (0.1)>0.99
OMEPRAZOLE (%)16 (1.8)43 (3.9)0.007
APIXABAN (%)5 (0.6)19 (1.7)0.022
PLAVIX (%)3 (0.3)10 (0.9)0.162
XARELTO (%)1 (0.1)8 (0.7)0.048
BRILINTA (%)1 (0.1)1 (0.1)>0.99
CILOSTAZOL (%)0 (0.0)2 (0.2)0.506
ASPIRIN (%)4 (0.5)102 (9.3)<0.001
CLOPIDOGREL (%)2 (0.2)14 (1.3)0.010
WARFARIN (%)2 (0.2)8 (0.7)0.200
ROSUVASTATIN (%)5 (0.6)30 (2.7)<0.001
PRAVASTATIN (%)5 (0.6)26 (2.4)0.002
LOVASTATIN (%)4 (0.5)11 (1.0)0.197
PITAVASTATIN (%)0 (0.0)1 (0.1)>0.99
FLUVASTATIN (%)0 (0.0)1 (0.1)>0.99
ATORVASTATIN (%)17 (1.9)120 (10.9)<0.001
SIMVASTATIN (%)7 (0.8)61 (5.6)<0.001
BENAZEPRIL (%)1 (0.1)3 (0.3)0.633
QUINAPRIL (%)2 (0.2)4 (0.4)0.698
RAMIPRIL (%)0 (0.0)6 (0.5)0.036
ENALAPRIL (%)1 (0.1)9 (0.8)0.050
LISINOPRIL (%)12 (1.4)132 (12.0)<0.001
FLUOXETINE (%)4 (0.5)8 (0.7)0.565
PAROXETINE (%)3 (0.3)3 (0.3)>0.99
SERTRALINE (%)3 (0.3)18 (1.6)0.007
CITALOPRAM (%)14 (1.6)32 (2.9)0.052
DULOXETINE (%)5 (0.6)11 (1.0)0.322
VENLAFAXINE (%)7 (0.8)4 (0.4)0.235
DESVENLAFAXINE (%)2 (0.2)1 (0.1)0.589
TRAZODONE (%)4 (0.5)13 (1.2)0.090
MIRTAZAPINE (%)1 (0.1)3 (0.3)0.633
BUPROPION (%)8 (0.9)21 (1.9)0.089
NORTRIPTYLINE (%)1 (0.1)2 (0.2)>0.99
DOXEPIN (%)0 (0.0)1 (0.1)>0.99
ARIPIPRAZOLE (%)1 (0.1)3 (0.3)0.633
QUETIAPINE (%)3 (0.3)5 (0.5)0.738
LITHIUM (%)0 (0.0)1 (0.1)>0.99
AMITRYPTILINE (%)9 (1.0)6 (0.5)0.299
ZOLEDRONIC ACID (%)2 (0.2)0 (0.0)0.199
IBANDRONATE (%)0 (0.0)1 (0.1)>0.99
ALENDRONATE (%)4 (0.5)20 (1.8)0.006
RISEDRONATE (%)0 (0.0)1 (0.1)>0.99
Bold denotes significance. Univariate associations between medications and periodontal disease status were assessed using a logistic regression model.
Table 5. Multivariable analysis for the association between medication intake and periodontal status (healthy vs. periodontitis), adjusted for age and sex.
Table 5. Multivariable analysis for the association between medication intake and periodontal status (healthy vs. periodontitis), adjusted for age and sex.
MedicationsAdjusted OR (95% CI)p-Value
BIPHOSPHONATES 1.179 (0.442, 3.141)0.864
PROTON PUMP INHIBITORS 1.491 (0.853, 2.607)0.483
ANTIDEPRESSANTS 0.966 (0.652, 1.431)0.864
ANTICOAGULANTS3.546 (1.982, 6.343)<0.001
STATINS 2.771 (1.877, 4.090)<0.001
ACE INHIBITORS 4.847 (2.785, 8.434)<0.001
Bold denotes significance. Multivariable regression models were explored, adjusting for the effects of age, sex and missing teeth at baseline. P-values were corrected for multiple comparisons using the Hochberg method.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chatzopoulos, G.S.; Jiang, Z.; Marka, N.; Wolff, L.F. Relationship of Medication Intake and Systemic Conditions with Periodontitis: A Retrospective Study. J. Pers. Med. 2023, 13, 1480. https://doi.org/10.3390/jpm13101480

AMA Style

Chatzopoulos GS, Jiang Z, Marka N, Wolff LF. Relationship of Medication Intake and Systemic Conditions with Periodontitis: A Retrospective Study. Journal of Personalized Medicine. 2023; 13(10):1480. https://doi.org/10.3390/jpm13101480

Chicago/Turabian Style

Chatzopoulos, Georgios S., Ziou Jiang, Nicholas Marka, and Larry F. Wolff. 2023. "Relationship of Medication Intake and Systemic Conditions with Periodontitis: A Retrospective Study" Journal of Personalized Medicine 13, no. 10: 1480. https://doi.org/10.3390/jpm13101480

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop